Senator Hawley Sought National Mifepristone Ban
The Missouri lawmaker proposed legislation to restrict the abortion drug following shifts in federal access.
Updated on Sept. 28, 2026 in Substance Abuse
Live Poll
Do you support a federal ban on the use of abortion medication in the United States?
Senator Josh Hawley has introduced the Safeguarding Women from Chemical Abortion Act, seeking a nationwide ban on the drug mifepristone. This move follows the Biden administration's decision to allow the drug to be distributed by mail.
Why it matters
Proponents of the ban argue that the prevalence of mail-order mifepristone undermines state-level abortion restrictions. Critics emphasize that the drug blocks progesterone, which is essential for sustaining a pregnancy.
Critics of the drug claim it causes life-threatening conditions in more than 1 in 10 cases. Additionally, a coalition of 50 pro-life leaders has recently called for stricter oversight from FDA leadership.
The players
Josh Hawley
He is a United States Senator from Missouri who has positioned himself as a vocal opponent of federal abortion pill access.
Heidi Overton
She is the nominee for FDA Commissioner who faces pressure from pro-life groups to restrict access to chemical abortion drugs.
Marty Makary
He is the current FDA Commissioner who previously committed to a formal review of the safety protocols surrounding mifepristone.
The details
The drug functions by blocking progesterone, effectively terminating a pregnancy. Senator Hawley introduced the Safeguarding Women from Chemical Abortion Act in March 2026 to challenge policies that allow mail distribution and remove in-person physician requirements.
Timeline
The Supreme Court overturned Roe v. Wade in 2022.
FDA Commissioner Marty Makary promised a mifepristone review in June 2025.
Senator Hawley introduced his legislative act in March 2026.
Fifty pro-life leaders issued a statement on Dr. Heidi Overton in September 2026.
An FDA safety review of the drug is expected after the 2026 midterms.
Deeper Dive
This story highlights the legislative strategy behind the Safeguarding Women from Chemical Abortion Act, which seeks to reverse recent federal regulatory expansions. This proposal represents a direct attempt to codify a federal prohibition on a medication previously permitted by FDA administrative shifts.
The proposed legislation could fundamentally alter how patients nationwide access reproductive healthcare if signed into law. Taxpayers and citizens may see a shift in federal regulations regarding drug approval processes and the scope of physician requirements.
The takeaway
The ongoing debate underscores the deep divide regarding the extent of federal authority over reproductive medicine. Readers should monitor future legislative developments and the outcome of the upcoming FDA safety review for potential changes to drug availability.
What happens next
The FDA is expected to conduct a formal safety review of mifepristone following the 2026 midterm elections.
Further reading
For more on the national debate surrounding regulation, visit the Substance Abuse section.
Live Poll
Do you support a federal ban on the use of abortion medication in the United States?
